Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Dual antiplatelet therapy is standard for myocardial infarction (MI) patients after resuscitation and therapeutic hypothermia (TH).
• Comparing intravenous cangrelor with oral P2Y12-inhibitors is crucial for optimizing antiplatelet effects and bleeding risk in this population.

Purpose of the Study:

• To prospectively compare the antiplatelet efficacy and bleeding risk of intravenous cangrelor versus oral P2Y12-inhibitors.
• To evaluate cangrelor's feasibility and effectiveness in patients with MI receiving TH.

Main Methods:

• Prospective comparison of two matched patient cohorts: CANGRELOR (NCT03445546) and ORAL P2Y12 (NCT02914795).
• Platelet function testing using light-transmittance aggregometry monitored over 4 days.
• Assessment of bleeding events using TIMI and BARC criteria, along with blood transfusion rates and hematological parameters.

Main Results:

• Stronger P2Y12-inhibition was observed with cangrelor compared to oral P2Y12-inhibitors at day 1 (ADP AUC: 26.0 vs. 160.9).
• This difference diminished as patients transitioned from cangrelor to oral agents.
• No significant differences in bleeding events (TIMI, BARC), blood transfusions, or changes in Hb/Hct were noted between groups.

Conclusions:

• Intravenous cangrelor is feasible and effective in resuscitated MI patients treated with TH.
• Cangrelor demonstrates superior platelet inhibition compared to oral P2Y12-inhibitors without elevating bleeding risk.
• This suggests cangrelor as a viable option for potent antiplatelet therapy in this high-risk cohort.